Soleno Therapeutics Faces Securities Fraud Lawsuit

Lawsuit alleges company misled investors about drug development progress

Mar. 30, 2026 at 10:51pm

Got story updates? Submit your updates here. ›

An extreme close-up of intricate, heavy banking machinery and financial ledgers, dramatically lit against a dark background, conceptually representing the complex financial systems and high-stakes investments in the pharmaceutical industry.The lawsuit against Soleno Therapeutics alleges the company misled investors about the progress of its drug development, exposing the high-stakes financial machinery behind the pharmaceutical industry.NYC Today

Institutional investors holding positions in Soleno Therapeutics, Inc. (NASDAQ: SLNO) have filed a securities fraud lawsuit against the company, alleging that it misled investors about the progress of its drug development programs.

Why it matters

The lawsuit could have significant financial and reputational consequences for Soleno Therapeutics if the allegations are proven true, potentially impacting the company's ability to raise capital and develop new treatments.

The details

The lawsuit claims that Soleno Therapeutics made false and misleading statements about the progress of its lead drug candidate, DCCR, for the treatment of Prader-Willi syndrome. The plaintiffs allege that the company downplayed the challenges and delays in the drug's development, leading investors to believe the product was closer to approval than it actually was.

  • The lawsuit was filed on March 30, 2026.

The players

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Got photos? Submit your photos here. ›

What’s next

The case is still in the early stages, and the court will need to determine if the allegations have merit and if the plaintiffs can prove their claims.

The takeaway

The lawsuit highlights the importance of transparency and accurate disclosure in the pharmaceutical industry, where investor confidence is crucial for funding drug development programs.